CSE:CGN - Post Discussion
Post by
tinkvid on Oct 08, 2021 3:00pm
FDA approval for Cognetivity's ICA
If CGN gets FDA approval for their ICA (
integrated cognitive assessment tool) the share price will no longer be .68 cents.
CGN has made some pretty promising relationships as of late....
HOLD ON TIGHT
With Merck, Eli Lilly and Apple currently testing.....the Race is on! - In June, donanemab received FDA Breakthrough Therapy Designation for Alzheimer's Disease.
Be the first to comment on this post